Hypertension Clinical Trials in Houston

Showing 101-120 of 203 trials

The Effect of a Scleral Lens on the Anterior Chamber Depth and Minimum Rim Width

NCT03926975

The purpose of this study is to evaluate the use of two instruments to measure changes in two ocular structures: 1) the anterior chamber depth (ACD) - measured using low coherence optical biometry, and 2) minimum rim width of the optic nerve head (MRW) - measured using optical coherence tomography. Changes in these ocular structures indicate fluctuations in intraocular pressure (IOP) and will be measured during scleral contact lens (SGP) wear to determine if SGP wear influences IOP. We hypothesize that a scleral lens increases the intraocular pressure (IOP) during active wear and that the ACD and MRW will also change.

Ocular Hypertension

University of Houston26 participantsStarted Jun 2018

Houston, Texas, United States

COMPLETEDPhase 2< 1 mile

The Effect of Sorafenib on Portal Pressure

NCT01714609

Sorafenib is approved by the US FDA for the treatment of unresectable (can not operate) liver cancer and for renal cell carcinoma. Sorafenib is a drug that inhibits the growth of cancer cells and prevents the formation of new blood vessels that would otherwise help the cancer spread. Studies in experimental animals have shown that sorafenib may also lower portal vein pressure (the pressure of the blood passing from the intestine through the liver.) This study seeks to determine if sorafenib lowers the blood pressure in liver blood vessels (portal vein pressure) in patients with cirrhosis who have high portal vein pressure. The study will also obtain information whether sorafenib is safe in this patient population. Half of the patients will be given sorafenib and half will be given a placebo (a pill without any medicine in it.) This allows a comparison of the reactions of people who take sorafenib to those who do not.

Clinically Significant Portal Hypertension

Yale University10 participantsStarted Aug 2011

New Haven, Connecticut, United States • West Haven, Connecticut, United States • Boston, Massachusetts, United States +3 more locations

The Effect of a Scleral Lens on the Anterior Chamber Depth and Minimum Rim Width

The Effect of Sorafenib on Portal Pressure

Hypertension Trials in Other Cities

The Long-term Study to Evaluate the Safety of Eplerenone in the Treatment of Hypertension in Children Aged 6 to 16 Years

Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose

Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma

Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction

Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome

Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma

Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

Registry to Evaluate INOmax in Newborn Babies With Pulmonary Hypertension

Dose-Ranging Study of the Bimatoprost Ocular Insert

An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert

Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study

52-104 Week Off-therapy Second Extension to Study CSPP100A2365

Patient and Provider Assessment of Lipid Management Registry

Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels

Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6

Other Conditions in Houston